2023

Attard, G. et al. (2023) Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. Lancet Oncology, 24(5), pp. 443-456. (doi: 10.1016/S1470-2045(23)00148-1)

2022

James, N. D. et al. (2022) Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476). International Journal of Cancer, 151(3), pp. 422-434. (doi: 10.1002/ijc.34018) (PMID:35411939)

James, N. D. et al. (2022) Docetaxel for nonmetastatic prostate cancer: long-term survival outcomes in the STAMPEDE randomized controlled trial. JNCI Cancer Spectrum, 6(4), pkac043. (doi: 10.1093/jncics/pkac043) (PMID:35877084) (PMCID:PMC9338456)

Parker, C. C. et al. (2022) Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLoS Medicine, 19(6), e1003998. (doi: 10.1371/journal.pmed.1003998) (PMID:35671327) (PMCID:PMC9173627)

Clarke, C. S. et al. (2022) Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data. PLoS ONE, 17(6), e0269192. (doi: 10.1371/journal.pone.0269192) (PMID:35653395) (PMCID:PMC9162346)

Attard, G. et al. (2022) Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet, 399(10323), pp. 447-460. (doi: 10.1016/S0140-6736(21)02437-5) (PMID:34953525) (PMCID:PMC8811484)

2019

Hoyle, A. P. et al. (2019) Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology, 76(6), pp. 719-728. (doi: 10.1016/j.eururo.2019.08.006) (PMID:31447077)

Griffiths, G. O., Cowan, R. A., Grigor, K. M., Uscinska, B. M., Sydes, M. and Russell, M. (2019) BA08: an open-label, single-arm, non-randomised, phase 2 trial of cisplatin, methotrexate and vinblastine (CMV) for pure squamous cell cancer of the urinary tract. PLoS ONE, 14(1), e0210785. (doi: 10.1371/journal.pone.0210785) (PMID:30650143) (PMCID:PMC6334943)

2018

Sydes, M. R. et al. (2018) Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Annals of Oncology, 29(5), pp. 1235-1248. (doi: 10.1093/annonc/mdy072) (PMID:29529169) (PMCID:PMC5961425)

Rulach, R. J. et al. (2018) Real world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer. BJU International, 121(2), pp. 268-274. (doi: 10.1111/bju.14025) (PMID:28940952)

2017

James, N. D. et al. (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine, 377(4), pp. 338-351. (doi: 10.1056/NEJMoa1702900) (PMID:28578639)

Mason, M. D. et al. (2017) Adding celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial. Journal of Clinical Oncology, 35(14), pp. 1530-1541. (doi: 10.1200/JCO.2016.69.0677) (PMID:28300506)

2014

Attard, G. et al. (2014) Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. European Urology, 66(5), pp. 799-802. (doi: 10.1016/j.eururo.2014.05.038)

2012

James, N.D. et al. (2012) Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncology, 13(5), pp. 549-558. (doi: 10.1016/S1470-2045(12)70088-8)

Dearnaley, D. et al. (2012) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology, 13(1), pp. 43-54. (doi: 10.1016/S1470-2045(11)70293-5)

2006

Pearson, S., Inglis, S.C., McLennan, S.N., Brennan, L., Russell, M., Wilkinson, D., Thompson, D.R. and Stewart, S. (2006) Prolonged effects of a home-based intervention in patients with chronic illness. Archives of Internal Medicine, 166(6), pp. 645-650.

2004

Russell, M. and Robb, A.J.P. (2004) Career pathways: supporting staff development from intern to consultant. In: 5th European Regional Conference of the Commonwealth Nurses Federation: A Commonwealth of Nations – The Commonwealth for Nurses Across Borders, St Julian's, Malta, 25-27 Mar 2004,

Articles

Attard, G. et al. (2023) Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. Lancet Oncology, 24(5), pp. 443-456. (doi: 10.1016/S1470-2045(23)00148-1)

James, N. D. et al. (2022) Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476). International Journal of Cancer, 151(3), pp. 422-434. (doi: 10.1002/ijc.34018) (PMID:35411939)

James, N. D. et al. (2022) Docetaxel for nonmetastatic prostate cancer: long-term survival outcomes in the STAMPEDE randomized controlled trial. JNCI Cancer Spectrum, 6(4), pkac043. (doi: 10.1093/jncics/pkac043) (PMID:35877084) (PMCID:PMC9338456)

Parker, C. C. et al. (2022) Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLoS Medicine, 19(6), e1003998. (doi: 10.1371/journal.pmed.1003998) (PMID:35671327) (PMCID:PMC9173627)

Clarke, C. S. et al. (2022) Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data. PLoS ONE, 17(6), e0269192. (doi: 10.1371/journal.pone.0269192) (PMID:35653395) (PMCID:PMC9162346)

Attard, G. et al. (2022) Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet, 399(10323), pp. 447-460. (doi: 10.1016/S0140-6736(21)02437-5) (PMID:34953525) (PMCID:PMC8811484)

Hoyle, A. P. et al. (2019) Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology, 76(6), pp. 719-728. (doi: 10.1016/j.eururo.2019.08.006) (PMID:31447077)

Griffiths, G. O., Cowan, R. A., Grigor, K. M., Uscinska, B. M., Sydes, M. and Russell, M. (2019) BA08: an open-label, single-arm, non-randomised, phase 2 trial of cisplatin, methotrexate and vinblastine (CMV) for pure squamous cell cancer of the urinary tract. PLoS ONE, 14(1), e0210785. (doi: 10.1371/journal.pone.0210785) (PMID:30650143) (PMCID:PMC6334943)

Sydes, M. R. et al. (2018) Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Annals of Oncology, 29(5), pp. 1235-1248. (doi: 10.1093/annonc/mdy072) (PMID:29529169) (PMCID:PMC5961425)

Rulach, R. J. et al. (2018) Real world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer. BJU International, 121(2), pp. 268-274. (doi: 10.1111/bju.14025) (PMID:28940952)

James, N. D. et al. (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine, 377(4), pp. 338-351. (doi: 10.1056/NEJMoa1702900) (PMID:28578639)

Mason, M. D. et al. (2017) Adding celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial. Journal of Clinical Oncology, 35(14), pp. 1530-1541. (doi: 10.1200/JCO.2016.69.0677) (PMID:28300506)

Attard, G. et al. (2014) Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. European Urology, 66(5), pp. 799-802. (doi: 10.1016/j.eururo.2014.05.038)

James, N.D. et al. (2012) Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncology, 13(5), pp. 549-558. (doi: 10.1016/S1470-2045(12)70088-8)

Dearnaley, D. et al. (2012) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology, 13(1), pp. 43-54. (doi: 10.1016/S1470-2045(11)70293-5)

Pearson, S., Inglis, S.C., McLennan, S.N., Brennan, L., Russell, M., Wilkinson, D., Thompson, D.R. and Stewart, S. (2006) Prolonged effects of a home-based intervention in patients with chronic illness. Archives of Internal Medicine, 166(6), pp. 645-650.

Conference Proceedings

Russell, M. and Robb, A.J.P. (2004) Career pathways: supporting staff development from intern to consultant. In: 5th European Regional Conference of the Commonwealth Nurses Federation: A Commonwealth of Nations – The Commonwealth for Nurses Across Borders, St Julian's, Malta, 25-27 Mar 2004,